Capivasertib

The addition of the AKT inhibitor capivasertib to first-line paclitaxel extended PFS and OS among a cohort of women with previously untreated, metastatic triple-negative breast cancer, according to results of the phase 2 PAKT trial published in Journal of Clinical Oncology.

Healio spoke with Roberto A. Leon-Ferre, MD, about recent approvals in breast cancer.